Quintiles celebrates two industry awards

By Kirsty Barnes

- Last updated on GMT

Related tags: Asia pacific, Southeast asia, Asia

Top international clinical research organisation (CRO) Quintiles is
celebrating after winning two industry awards for its work in the
Asia Pacific region.

The company's East Asia subsidiary has been named the Asia Pacific region's multinational clinical trials service provider of the year and multinational CRO of the year by the consulting firm Frost & Sullivan.

The firm has been working hard to cement itself in the expand burgeoning Asian clinical trials arena after already establishing itself as the largest CRO in the pharma industry's other lucrative growth market, India.

Covance, Kendle and PRA are among other top CROs vying for new business in the region.

Biopharmaceutical companies are increasingly interested in integrating China, Japan, Singapore, India and other Asian Pacific countries into their global studies in order to increase the speed of drug development and reduce study costs.

"The area is ideal for clinical research,"​ said Michael Stibilj, executive director of Southeast Asia Clinical Development.

"It has the right mix of excellent hospital infrastructure, highly motivated investigators, a stable regulatory environment and a broad spectrum of diseases common in the developing and developed world,"​ he said.

Last year Quintiles started 76 new clinical trials and now has more than 200 trials ongoing and 320 regular clinical research employees in the Asia Pacific region.

The company also opened new offices in Vietnam and Indonesia, adding to its existing offices in Australia, New Zealand, China, Korea, Malaysia, Philippines, Singapore, Taiwan and Thailand.

Since 1993, the Quintiles clinical team in Asia Pacific has completed over 500 clinical trials involving about 2,500 sites and more than 60,000 patients.

Frost & Sullivan said it presents the awards to companies that demonstrate "best practices in their industry, using the diligence, commitment and innovative business strategies required to advance in the global marketplace."

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us


View more